Birdwatch Note
2024-12-26 15:33:22 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
総接種数、2020年の年間死亡率、社員総数から社内の接種3日以内の無関係死亡数は約1.6人と推計できます https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/kekkaku-kansenshou/yobou-sesshu/syukeihou_00002.html https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei20/dl/03_h1.pdf https://www.meiji-seika-pharma.co.jp/corporate/outline/ よって、社員1名の接種3日後死亡はワクチンの危険性を示しません。 著者と思しき人物はド素人を自認しています https://x.com/yaminodaddy/status/1370366068720427015 書籍名によれば開発担当ではなく、前書きによれば非公開情報や内部情報もないので、「内部事情について、最も知っている」は嘘です https://www.amazon.co.jp/dp/B0DHCYPZJ2?asin=B0DHCYPZJ2&revisionId=e84ae297&format=3&depth=1 https://x.com/WideRangeThink/status/1847501454090858990 「複数の現役社員」は出版社も把握している嘘でした https://www.meiji-seika-pharma.co.jp/pressrelease/2024/detail/pdf/241219_01.pdf https://www.amazon.co.jp/dp/B0DHCYPZJ2?asin=B0DHCYPZJ2&revisionId=e84ae297&format=3&depth=1 コスタイベ(レプリコンワクチン)の安全性と有効性は治験で良好と評価されています https://doi.org/10.1038/s41467-024-47905-1 https://www.mhlw.go.jp/content/10906000/001316061.pdf https://www.pmda.go.jp/drugs/2024/P20240917001/780009000_30500AMX00282_A100_1.pdf https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#20 以下、詳細まとめ https://togetter.com/li/2482974 https://togetter.com/li/2484204 https://togetter.com/li/2485069 https://togetter.com/li/2416068
Written by EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1872206438736728323
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1872304706804236787
- noteId - 1872304706804236787
- participantId -
- noteAuthorParticipantId - EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00 Participant Details
- createdAtMillis - 1735227202498
- tweetId - 1872206438736728323
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- 総接種数、2020年の年間死亡率、社員総数から社内の接種3日以内の無関係死亡数は約1.6人と推計できます https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/kekkaku-kansenshou/yobou-sesshu/syukeihou_00002.html https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei20/dl/03_h1.pdf https://www.meiji-seika-pharma.co.jp/corporate/outline/ よって、社員1名の接種3日後死亡はワクチンの危険性を示しません。 著者と思しき人物はド素人を自認しています https://x.com/yaminodaddy/status/1370366068720427015 書籍名によれば開発担当ではなく、前書きによれば非公開情報や内部情報もないので、「内部事情について、最も知っている」は嘘です https://www.amazon.co.jp/dp/B0DHCYPZJ2?asin=B0DHCYPZJ2&revisionId=e84ae297&format=3&depth=1 https://x.com/WideRangeThink/status/1847501454090858990 「複数の現役社員」は出版社も把握している嘘でした https://www.meiji-seika-pharma.co.jp/pressrelease/2024/detail/pdf/241219_01.pdf https://www.amazon.co.jp/dp/B0DHCYPZJ2?asin=B0DHCYPZJ2&revisionId=e84ae297&format=3&depth=1 コスタイベ(レプリコンワクチン)の安全性と有効性は治験で良好と評価されています https://doi.org/10.1038/s41467-024-47905-1 https://www.mhlw.go.jp/content/10906000/001316061.pdf https://www.pmda.go.jp/drugs/2024/P20240917001/780009000_30500AMX00282_A100_1.pdf https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#20 以下、詳細まとめ https://togetter.com/li/2482974 https://togetter.com/li/2484204 https://togetter.com/li/2485069 https://togetter.com/li/2416068
Note Ratings
| rated at | rated by | |
| 2024-12-26 17:58:46 -0600 | Rating Details | |
| 2024-12-26 17:38:26 -0600 | Rating Details | |
| 2024-12-26 17:13:49 -0600 | Rating Details | |
| 2024-12-26 15:51:43 -0600 | Rating Details | |
| 2024-12-26 15:24:31 -0600 | Rating Details | |
| 2024-12-26 14:29:07 -0600 | Rating Details | |
| 2024-12-26 10:16:27 -0600 | Rating Details | |
| 2024-12-27 06:59:32 -0600 | Rating Details | |
| 2024-12-27 02:44:21 -0600 | Rating Details | |
| 2024-12-26 21:17:00 -0600 | Rating Details | |
| 2024-12-26 20:39:17 -0600 | Rating Details | |
| 2024-12-26 19:18:55 -0600 | Rating Details | |
| 2024-12-26 18:19:18 -0600 | Rating Details | |
| 2024-12-26 15:07:56 -0600 | Rating Details | |
| 2024-12-26 11:55:54 -0600 | Rating Details | |
| 2024-12-26 09:56:27 -0600 | Rating Details | |
| 2024-12-27 06:54:57 -0600 | Rating Details | |
| 2024-12-27 02:53:24 -0600 | Rating Details | |
| 2024-12-26 22:09:50 -0600 | Rating Details | |
| 2024-12-26 21:36:38 -0600 | Rating Details | |
| 2024-12-26 20:34:15 -0600 | Rating Details | |
| 2024-12-26 19:47:46 -0600 | Rating Details | |
| 2024-12-26 19:08:52 -0600 | Rating Details | |
| 2024-12-27 22:42:24 -0600 | Rating Details | |
| 2024-12-27 03:11:38 -0600 | Rating Details | |
| 2024-12-27 02:37:10 -0600 | Rating Details | |
| 2024-12-26 20:23:03 -0600 | Rating Details | |
| 2024-12-26 18:05:49 -0600 | Rating Details | |
| 2024-12-26 17:40:37 -0600 | Rating Details | |
| 2024-12-26 14:16:58 -0600 | Rating Details | |
| 2024-12-26 11:32:24 -0600 | Rating Details | |
| 2024-12-27 20:24:49 -0600 | Rating Details | |
| 2024-12-26 23:17:46 -0600 | Rating Details | |
| 2024-12-26 22:15:27 -0600 | Rating Details | |
| 2024-12-26 21:00:29 -0600 | Rating Details | |
| 2024-12-26 20:23:54 -0600 | Rating Details | |
| 2024-12-26 20:18:05 -0600 | Rating Details | |
| 2024-12-26 19:52:55 -0600 | Rating Details | |
| 2024-12-26 18:04:20 -0600 | Rating Details | |
| 2024-12-26 17:49:51 -0600 | Rating Details | |
| 2024-12-26 17:46:30 -0600 | Rating Details | |
| 2024-12-26 16:26:57 -0600 | Rating Details | |
| 2024-12-26 15:47:56 -0600 | Rating Details | |
| 2024-12-26 15:16:51 -0600 | Rating Details | |
| 2024-12-26 14:06:03 -0600 | Rating Details | |
| 2024-12-26 13:07:12 -0600 | Rating Details |